What changed
What changedКомпанія Medline Inc. погодилася викупити акції та частки на суму $200 млн у межах приватної угоди, яка залежить від завершення вторинного розміщення акцій. Це рішення дозволить компанії скасувати частину викуплених паперів, а сама угода про викуп була схвалена аудиторським комітетом ради директорів.

What changedMedline Inc. reported results for the third quarter of 2026: revenue rose to $7.86 billion. Meanwhile, the company’s operating income fell 12.9% compared to the same quarter last year and 26.3% for the first nine months of the year compared to the same period in 2025.

What changedMedline Inc. revenue rose 10.4% to $7.9 billion in the third quarter of 2026. Nine-month net income fell 28.8% to $696 million, largely driven by $316 million in losses from a fire at the company’s distribution center in Tracy, California.

Deals & ownershipGIC Private Ltd, GIC Special Investments Pte Ltd and Hux Investment Pte Ltd, each a 10% owner, sold 20,678,630 shares for $721,644,227.38 between Oct 2‑6, 2026, and sold another 7,816,987 shares for $274,767,093.05 on Oct 8, 2026.

Company history
October 2026
Medline Inc. experienced significant insider stock divestments, board leadership changes, and a voluntary product withdrawal during October 2026.
- Between October 2, 2026 and October 6, 2026, insiders disposed of 20,678,630 shares in 5 transactions for a total value of 721,644,227.38 USD, leaving 77,225,493 shares owned. Source
- On October 8, 2026, an insider disposed of 7,816,987 shares at a weighted average price of 35.15 USD, totaling 274,767,093.05 USD, leaving 69,408,506 shares owned. Source
- On October 13, 2026, Joseph P. Baratta notified the Board of Medline Inc. of his decision to resign from the Board, effective December 31, 2026. Source
- On October 14, 2026, Medline Inc. initiated a voluntary field action to remove and discontinue Medline Brand beds and accessories from its Front Line Care category, which generated approximately $60 million in net sales for the twelve months ended June 27, 2026. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
The secondary offering of Class A common stock is expected to close on November 23, 2026.
Said November 18, 2026 · Period named: November 23, 2026 · Source · Our article
Not yet checked against later reports.
Medline and Medline Holdings intend to repurchase equity interests in a total amount based on a $200,000,000 quotient, determined by the price of secondary shares in an underwritten offering.
Said November 18, 2026 · Source · Our article
Not yet checked against later reports.
Full year 2026 Adjusted EBITDA guidance excludes $324 million of net tariff refunds recorded through the first nine months of 2026.
Said November 4, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
Reaffirming Adjusted EBITDA guidance of $3.3 billion to $3.4 billion.
Said November 4, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
Raising full year 2026 Organic Sales guidance to 10.0% to 10.5%.
Said November 4, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Changes in risk factors
The 10-Q filed November 4, 2026 compared with the 10-Q filed August 5, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Added (25)
- | September 26, 2026 | | September 27, 2025 | | September 26, 2026 | | September 27, 2025
- Issuance of shares under employee stock plans | 1 | | — | | — | | — | | — | | — | | — | | — | | —
- Balance, September 26, 2026 | 879 | $ | — | | 437 | $ | — | | $ | 11,428 | | $ | 377 | | $ | (4) | | $ | 7,585 | | $ | 19,386
Dropped (14)
- We file electronically with the U.S. Securities and Exchange Commission (the “SEC”) our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements and other forms or reports as required. Our filings with the SEC are available to the public at the SEC’s website at www.sec.gov. We also use our investor relations website at ir.medline.com, press releases, public conference calls and webcasts, and social media as routine channels of distribution to communicate important, and often material, information about Medline to investors and the public,…
- Balance, March 28, 2026 | 846 | $ | — | | 468 | | $ | — | | $ | 11,132 | | $ | 122 | | $ | 18 | | $ | 8,077 | | $ | 19,349
- Balance, March 29, 2025 | 128 | $ | 239 | | 104 | $ | 129 | | $ | 368 | | 16,723 | $ | 16,294 | | 764 | $ | 140 | | 23 | $ | 49 | | $ | 7 | | $ | 16,490
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| October 15, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Insider trades
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|
| October 8, 2026 | GIC Private Ltd | Sale | 7,816,987 | $35.15 | $274,767,093 | SEC |
| October 6, 2026 | GIC Private Ltd | Sale | 20,678,630 | $34.90 | $721,644,227 | SEC |
All insider trades →
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| Capital Research Global Investors | 47,756,528 | $1,657,164,017 | +19.5% | Q3 2026 |
| Fidelity (FMR) | 44,424,934 | $1,541,545,193 | -5.4% | Q3 2026 |
| BlackRock | 26,551,775 | $921,346,611 | +0.6% | Q3 2026 |
| State Street | 9,878,097 | $342,769,966 | +16.9% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 8,475,413 | $334,270,289 | — | Q2 2026 |
| Geode Capital Management | 9,068,896 | $314,022,775 | +14.1% | Q3 2026 |
| Citadel Advisors | 2,082,861 | $72,275,277 | +6,291.9% | Q3 2026 |
| Soros Fund Management | 1,003,364 | $34,816,731 | -38.8% | Q3 2026 |
| Renaissance Technologies | 441,100 | $15,306,170 | +207.0% | Q3 2026 |
| Millennium Management | 207,758 | $7,209,203 | -80.5% | Q3 2026 |
| Two Sigma Investments | 92,170 | $3,198,299 | -52.6% | Q3 2026 |
| Wellington Management | 62,515 | $2,465,591 | — | Q2 2026 |
| Bridgewater Associates | 20,398 | $707,811 | +2.8% | Q3 2026 |
| T. Rowe Price | 3,541,067 | $122,876 | -28.1% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.